A cancer survivor shares what to say, what not to say and how listening can help support someone through cancer treatment and beyond.
|Videos|April 9, 2021
Raising Awareness Around Liver Cancer and Disease
Author(s)Kristie L. Kahl
CURE spoke with Dr. Marty T. Sellers and Dr. Laura M. Kulik, on behalf of the Blue Faery, about liver cancer and disease – its treatments, causes and areas outside of therapy.
Advertisement
Advertisement
Related to this article
Bravnetsa is the first radioligand therapy approved through the FDA's abbreviated pathway, adding an option for adults with SSTR-positive GEP-NETs.
The investigational drug, first developed for brain cancer, is being tested to see whether it can make resistant tumors respond to treatment again.
Cancer research is increasingly looking beyond the tumor to understand the whole body, immune system and patient experience.
AI is becoming a growing part of cancer care. Learn how doctors are using it to navigate complex treatment decisions and support patients.
In patients with advanced ROS1-positive lung cancer who had not previously received a ROS1-targeted drug, Jideytro also shrank tumors that had spread to the brain in all 10 evaluable patients.
An estimated 70% of patients with stage 3 lung cancer do not see their tumors respond to standard treatment. An expert explains why, and what a new approach aims to change.
Living with stage IV kidney cancer for 10 years, one survivor shares how he manages scanxiety, uncertainty and the waiting between scans.
Advertisement
Advertisement
Trending on CURE
1
The Growing Role of AI in Cancer Care
2
Blood Cancer Treatments in the FDA Pipeline: What Could Come Next
3
Why Some Stage 3 Lung Cancers Don't Respond to Treatment, and What Researchers Are Trying Next
4
3 More Lung Cancer Breakthroughs From WCLC 2026
5